Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CellaVision AB ( (SE:CEVI) ) has provided an update.
CellaVision’s Q2 2025 report shows a robust performance with a 7.6% organic sales growth despite mixed regional results. The APAC region saw significant growth due to increased shipments to China, while the Americas and EMEA experienced moderate growth. The company is advancing strategic priorities, including clinical trials for bone marrow analysis and software upgrades, and maintains a strong financial position. The departure of CFO Magnus Blixt marks a significant leadership change.
More about CellaVision AB
CellaVision AB operates in the healthcare sector, focusing on digital cell morphology solutions. The company provides innovative diagnostic tools that enhance laboratory workflows, particularly in hematology, with a strong market presence in regions like APAC, Americas, and EMEA.
Average Trading Volume: 20,368
Current Market Cap: SEK4.31B
Learn more about CEVI stock on TipRanks’ Stock Analysis page.